| Medication | Form | Major brand names | Duration |
|---|---|---|---|
| Testosterone | Aqueous suspension | Andronaq, Sterotate, Virosterone | 2–3 days |
| Testosterone propionate | Oil solution | Androteston, Perandren, Testoviron | 3–4 days |
| Testosterone phenylpropionate | Oil solution | Testolent | 8 days |
| Testosterone isobutyrate | Aqueous suspension | Agovirin Depot, Perandren M | 14 days |
| Mixed testosterone estersa | Oil solution | Triolandren | 10–20 days |
| Mixed testosterone estersb | Oil solution | Testosid Depot | 14–20 days |
| Testosterone enanthate | Oil solution | Delatestryl | 14–28 days |
| Testosterone cypionate | Oil solution | Depovirin | 14–28 days |
| Mixed testosterone estersc | Oil solution | Sustanon 250 | 28 days |
| Testosterone undecanoate | Oil solution | Aveed, Nebido | 100 days |
| Testosterone buciclated | Aqueous suspension | 20 Aet-1, CDB-1781e | 90–120 days |
| Nandrolone phenylpropionate | Oil solution | Durabolin | 10 days |
| Nandrolone decanoate | Oil solution | Deca Durabolin | 21–28 days |
| Methandriol | Aqueous suspension | Notandron, Protandren | 8 days |
| Methandriol bisenanthoyl acetate | Oil solution | Notandron Depot | 16 days |
| Metenolone acetate | Oil solution | Primobolan | 3 days |
| Metenolone enanthate | Oil solution | Primobolan Depot | 14 days |
| Note: All are via i.m. injection. Footnotes: a = TP, TV, and TUe. b = TP and TKL. c = TP, TPP, TiCa, and TD. d = Studied but never marketed. e = Developmental code names. Sources: Main: [1][2][3][4] Additional: [5][6][7][8] | |||
Template documentationSee also
- Template:Parenteral potencies and durations of steroidal estrogens
- Template:Parenteral potencies and durations of progestogens
- Template:Structural properties of major testosterone esters
- Template:Structural properties of major anabolic steroid esters
References
- ^ Schuermann H, Doepfmer R (1960). Fertilitätsstörungen beim Manne. Springer-Verlag. pp. 260–. ISBN 978-3-642-94784-1.
- ^ Ufer J (1960). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis. Gruyter. p. 153.
- ^ Pschyrembel W (1968). Praktische Gynäkologie: für Studierende und Ärzte. Walter de Gruyter. p. 600. ISBN 978-3-11-150424-7.
- ^ Wright JC, Burgess DJ (29 January 2012). Long Acting Injections and Implants. Springer Science & Business Media. pp. 114–. ISBN 978-1-4614-0554-2.
- ^ Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. pp. 385–394. ISBN 978-0-9828280-1-4.
- ^ Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, et al. (May 2007). "More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate". Asian Journal of Andrology. 9 (3): 291–7. doi:10.1111/j.1745-7262.2007.00275.x. PMID 17486268.
- ^ Behre HM, Nieschlag E (November 1992). "Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester". The Journal of Clinical Endocrinology and Metabolism. 75 (5): 1204–10. doi:10.1210/jcem.75.5.1430080. PMID 1430080.
- ^ Nieschlag E, Behre H (29 June 2013). Andrology: Male Reproductive Health and Dysfunction. Springer Science & Business Media. pp. 412–. ISBN 978-3-662-04491-9.
Under the auspices of WHO a synthesis programme identified testosterone buciclate as a testosterone ester with long-lasting effectiveness. First tested in monkeys and then in hypogonadal patients, it showed a long effective phase of 3–4 months after a single injection.